Low-Cost HIV Alliance To Restore GSK’s China Image?
This article was originally published in PharmAsia News
Executive Summary
Although it is still awaiting approval from the China FDA for its widely-sold and fast-growing HIV drug, GSK unit ViiV has linked a deal with a Chinese firm to manufacture low-priced Tivicay in the country. The arrangement could be a preemptive move as China is increasing pressure on the prices of costly new therapies for infectious diseases.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.